8-K: Clover Health Reports 2025 Profit, Forecasts 2026 GAAP Net Income

Clover Health reported strong full year 2025 financial results, achieving Adjusted EBITDA profitability and significant membership growth, while projecting its first-ever full year of GAAP Net Income profitability in 2026.

Summary

• Achieved full year 2025 Adjusted EBITDA profitability of $22 million.
• Medicare Advantage membership grew 38% year-over-year in 2025 to 113,803 members.
• Total revenues for full year 2025 increased 40% year-over-year to $1.9 billion.
• Reported a GAAP Net loss of $86 million for full year 2025.
• Provided full year 2026 guidance projecting average Medicare Advantage membership between 154,000 and 158,000, representing 46% growth year-over-year at the midpoint.
• Forecasted total revenues for 2026 between $2.81 billion and $2.92 billion, indicating 49% growth year-over-year at the midpoint.
• Projected 2026 Adjusted EBITDA profitability between $50 million and $70 million.
• Anticipated GAAP Net Income for 2026 to be between $0 million and $20 million, marking the first-ever full year of GAAP Net Income profitability.
• Achieved industry-leading 2026 AEP (Annual Enrollment Period) growth of 53% year-over-year, supported by strong returning member retention.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to strong membership and revenue growth, achieving Adjusted EBITDA profitability in 2025, and providing optimistic guidance for 2026, including the first projected GAAP Net Income profitability.

Positives

• Achieved full year 2025 Adjusted EBITDA profitability of $22 million.
• Medicare Advantage membership grew significantly by 38% year-over-year in 2025, reaching 113,803 members.
• Total revenues increased substantially by 40% year-over-year in 2025, reaching $1.9 billion.
• Insurance revenue grew 41% year-over-year in 2025.
• Achieved industry-leading 2026 AEP growth of 53% year-over-year, coupled with strong returning member retention.
• Projecting the first-ever full year of GAAP Net Income profitability in 2026, with guidance between $0 million and $20 million.
• Forecasted significant growth for 2026, including 46% Medicare Advantage membership growth, 49% total revenue growth, and 38% consolidated gross profit growth at the midpoint.
• Adjusted SG&A as a percentage of Total revenues improved from 21.5% in 2024 to 17.4% in 2025, demonstrating operational leverage.

Negatives

• Reported a full year 2025 GAAP Net loss of $86 million, an 84.7% increase from the $46.3 million loss in 2024.
• Consolidated Gross profit decreased by 2.4% year-over-year in 2025 to $355.9 million.
• Adjusted EBITDA decreased by 69.0% year-over-year in 2025, from $70.1 million to $21.7 million.
• Adjusted Net Income from continuing operations decreased by 70.7% year-over-year in 2025, from $68.2 million to $20.0 million.
• Total cash, cash equivalents, and investments decreased by 26.9% from $437.6 million at December 31, 2024, to $319.9 million at December 31, 2025.
• Insurance Benefits Expense Ratio (BER) increased from 81.2% in 2024 to 90.9% in 2025.
• Normalized Insurance BER increased from 84.2% in 2024 to 91.5% in 2025.

Risks

• Expectations regarding results of operations, financial condition, and cash flows may not be met.
• Uncertainties regarding the development and management of the business.
• Potential negative effects on revenue, profit margins, cash flows, and business from current, pending, or future legislation, regulations, or policies related to healthcare, Medicare, and medical loss ratios.
• Challenges in successfully entering new service markets and managing operations.
• Anticipated trends and challenges in the business and the markets in which the company operates.
• Ability to effectively manage the beneficiary base and provider network.
• Ability to maintain and increase adoption and use of Clover Assistant, including its expansion for external payors and providers under the Counterpart Assistant brand.
• Realization of anticipated benefits associated with the use of Clover Assistant, particularly its ability to manage medical expenses.
• Ability to maintain or improve Star Ratings or otherwise continue to improve the financial performance of the business.
• Ability to develop new features and functionality that meet market needs and achieve market acceptance.
• Ability to retain and hire necessary employees and staff operations appropriately.
• Timing and amount of certain investments in growth.
• Outcome of any known and unknown litigation and regulatory proceedings.
• Ability to maintain, protect, and enhance intellectual property.
• General economic conditions and uncertainty.
• Persistent high inflation and fluctuating interest rates.
• Geopolitical uncertainty and instability.

Future Outlook

Clover Health anticipates achieving its first full year of GAAP Net Income profitability in 2026, with projected net income between $0 million and $20 million. This positive outlook is driven by expected improvements in cohort economics, strong returning member retention, a more favorable rate environment, and continued operating leverage as the company scales. The company forecasts market-leading membership growth and significant increases in total revenues and Adjusted EBITDA for 2026.

Management Comments

• "Our results in 2025 validate the scalability of our differentiated model, despite some headwinds during the year." Andrew Toy, CEO.
• "By replicating this strategy in 2026, with confidence in our pricing and benefit design, we anticipate scaling Clover Assistant-powered care to more seniors and have positioned Clover to achieve our first full year of GAAP Net Income profitability in 2026." Andrew Toy, CEO.
• "During 2025, we demonstrated financial resilience, supported by continued Adjusted EBITDA profitability, a controlled underlying medical cost trend, and Medicare Advantage membership growth significantly above market." Peter Kuipers, CFO.
• "Looking to 2026, we expect improving cohort economics, strong returning member retention, a more favorable rate environment, and continued operating leverage as we scale, establishing a strong path to continued market-leading membership growth and full-year 2026 GAAP Net Income profitability." Peter Kuipers, CFO.

Industry Context

StockSavvy.ai notes that Clover Health's reported 2026 AEP growth of 53% year-over-year is highlighted as 'industry-leading,' suggesting strong competitive positioning in the Medicare Advantage market. The focus on 'Clover Assistant-powered care' aligns with a broader industry trend towards technology-driven healthcare solutions for improved outcomes and cost management. The company's pursuit of GAAP Net Income profitability in 2026, following Adjusted EBITDA profitability in 2025, indicates a maturation phase for a growth-focused healthcare technology firm, aiming for sustainable financial health in a competitive and regulated sector.

Comparison to Industry Standards

• Clover Health's 2026 AEP growth of 53% year-over-year is stated as 'industry-leading,' implying it surpasses the average growth rates of major Medicare Advantage providers such as UnitedHealthcare, Humana, and Aetna (CVS Health).
• The company's goal of achieving GAAP Net Income profitability in 2026 positions it to join more established, profitable players in the health insurance sector, moving beyond the typical early-stage, high-growth, loss-making profile often seen in health tech startups.
• The emphasis on the Clover Assistant platform for managing medical expenses and improving health outcomes reflects a trend seen in other tech-enabled healthcare companies like Oscar Health or Bright Health Group, though Clover Health claims differentiated results in areas like Medication Adherence and chronic disease management.

Legal Proceedings

• The company acknowledges the risk of outcomes from any known and unknown litigation and regulatory proceedings, as detailed in its most recent Annual Report on Form 10-K.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to projected GAAP Net Income profitability and continued strong growth in membership and revenues.
• Members (Customers): Continued focus on 'Clover Assistant-powered care' and 'wide-network PPO' plans aims to improve health outcomes and access to high-quality healthcare.
• Employees: Continued growth and scaling of operations may lead to job stability and potential expansion opportunities.
• Providers: Expansion of Clover Assistant to external payors and providers (Counterpart Assistant) could create new partnerships and revenue streams for healthcare providers.

Next Steps

• Management will host a conference call on February 26, 2026, at 5:00 PM ET to discuss operating results and other business highlights.
• The company will present at the 2026 Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 9:20 a.m. Eastern Time.
• Continued scaling of Clover Assistant-powered care to more seniors in 2026.
• Replication of the 2025 strategy in 2026 with confidence in pricing and benefit design.

Key Dates

Recommendation

The filing demonstrates strong operational momentum with significant membership and revenue growth in 2025, coupled with the achievement of Adjusted EBITDA profitability. The 2026 guidance is particularly compelling, projecting the company's first-ever GAAP Net Income profitability and continued market-leading growth in Medicare Advantage membership and total revenues. This trajectory suggests a positive inflection point for the company, indicating improving financial health and scalability of its technology-driven model, making it an attractive investment.

Keywords

Medicare Advantage, healthcare technology, Clover Assistant, health insurance, financial results, earnings, CLOV, profitability, membership growth, Adjusted EBITDA, GAAP Net Income, PPO plans, Counterpart Health